DHR earnings: next report 2026-10-20, real EPS beat/miss history, analyst consensus Buy, P/E 34.52. Updated 2026-07-23.
Danaher (DHR) Research Hub
Danaher (DHR) trades on NYSE, US in the Healthcare (Medical - Diagnostics & Research) sector. As of 2026-09-11, shares last closed at 200.06 USD (-2.34%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 34.52, market cap 124.80B. This hub links to the full technical, earnings and options research available for DHR.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Diagnostics & Research) |
|---|---|
| Exchange | NYSE, US |
| Last close | 200.06 USD (-2.34%) |
| 52-week range | 173 USD – 220.25 USD |
| Trend regime | Range |
| 14-day RSI | 45.5 (Neutral) |
| Trailing P/E | 34.52 |
| Market cap | 124.80B |
| Dividend yield | 0.80% |
| Next earnings | 2026-10-20 |
Available research for DHR
Covered Call on DHR: how it works, illustrative setup around the real 200.06 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DHR: how it works, illustrative setup around the real 200.06 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DHR: how it works, illustrative setup around the real 200.06 USD price, max profit/loss, breakeven and when to use it. Educational.
DHR technical analysis: range, last 200.06 USD, RSI 45.5, 52w range 173 USD–220.25 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is DHR in?
Danaher (DHR) is classified under Healthcare (Medical - Diagnostics & Research), listed on NYSE, US.
Is DHR in an uptrend or downtrend?
As of 2026-09-11, DHR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DHR's trailing P/E ratio?
DHR's trailing P/E is 34.52, with a market cap of 124.80B. See the earnings research page for full valuation detail.
When does DHR next report earnings?
DHR is next scheduled to report earnings on 2026-10-20, with a consensus EPS estimate of 1.93 USD.